The goal of this project is to develop a drug candidate that can be used for the treatment of Pseudomonas aeruginosa biofilms in cystic fibrosis (CF) patients. Recurrent lung infections caused by biofilm-forming P. aeruginosa often result in progressive decline in lung function eventually leading to respiratory arrest and death. The current treatment for CF lung infections is limited to antibiotics, which are effective against planktonic bacteria but not bacterial cells in a biofilm. Given the anti-biofilm properties of the lead peptide presented here, we expect the developed drug candidate will prevent and/or eradicate biofilms, either alone or as an adjuvant to enhance the efficacy of existing antibiotics. In the frame of this project, we aim to develop the drug candidate to the stage where it will be ready for preclinical research in animal models.